Arcus Biosciences (RCUS) Tops Q4 EPS by 21c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($0.89), $0.21 better than the analyst estimate of ($1.10). Revenue for the quarter came in at $33 million versus the consensus estimate of $35.71 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• Vishay launches new TVS series for automotive and industrial use
• Casey's General Stores (CASY) PT Lowered to $810 at BMO Capital